Reuters -- MannKind Corp (MNKD.O) faces a crucial test next week as U.S. regulators prepare to rule on the company’s inhaled insulin device, and many investors are betting it will not be approved.
Reuters -- MannKind Corp (MNKD.O) faces a crucial test next week as U.S. regulators prepare to rule on the company’s inhaled insulin device, and many investors are betting it will not be approved.
